Hector Marchand, MD
Cardiovascular Disease · la Porte, INNPI 1538181359
Payments from drug & device makers
Across 325 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$925
- Amgen$923
- Merck$568
- Pfizer$472
- Novo Nordisk$396
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,543100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $1,026 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 88 | $925 |
| Amgen | 58 | $923 |
| Merck | 33 | $568 |
| Pfizer | 32 | $472 |
| Novo Nordisk | 10 | $396 |
| Novartis | 17 | $369 |
| Edwards Lifesciences | 5 | $290 |
| Esperion Therapeutics, Inc. | 8 | $191 |
| Johnson & Johnson | 7 | $144 |
| Lilly USA, LLC | 8 | $144 |
| Otsuka America Pharmaceutical, Inc. | 2 | $143 |
| Actelion Pharmaceuticals US, Inc. | 3 | $133 |
| AstraZeneca | 9 | $122 |
| W. L. Gore & Associates, Inc. | 1 | $113 |
| Boehringer Ingelheim | 6 | $104 |
| Axsome Therapeutics, Inc. | 2 | $62 |
| Lundbeck LLC | 3 | $62 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $48 |
| Amarin Pharma, Inc. | 4 | $47 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Bridgebio Pharma, Inc. | 1 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Biotronik NRO, Inc. | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Insulet Corporation | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| AbbVie | 1 | $13 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$381
- WATCHMAN Access System$149
- Edwards SAPIEN 3 Transcatheter Heart Valve$131
- NEXLIZET$125
- NEXLETOL$125
- REXULTI$125
- Ozempic$125
- LEQVIO$125
- CARDIOFORM Septal Occluder$113
- Watchman$112
How this compares
$6,557 in reported general payments places this provider in the 65th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 198 | $232,017 |
| EntrestoSacubitril/Valsartan | 152 | $228,428 |
| XareltoRivaroxaban | 133 | $149,855 |
| Repatha SureclickEvolocumab | 108 | $111,798 |
| MultaqDronedarone Hcl | 38 | $45,362 |
| MounjaroTirzepatide | 34 | $36,109 |
| BrilintaTicagrelor | 25 | $26,295 |
| FarxigaDapagliflozin Propanediol | 22 | $26,230 |
| Praluent PenAlirocumab | 24 | $21,924 |
| JardianceEmpagliflozin | 23 | $21,188 |
| VerquvoVericiguat | 20 | $18,302 |
| Ezetimibe | 254 | $7,846 |
| Ranolazine ErRanolazine | 29 | $5,145 |
| Metoprolol Succinate | 475 | $4,975 |
| Flecainide Acetate | 76 | $4,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $472 | $232,017198 claims |
| NovartisEntresto | $369 | $228,428152 claims |
| Johnson & JohnsonXarelto | $144 | $149,855133 claims |
| AstraZenecaBrilinta, Farxiga | $122 | $52,52447 claims |
| Sanofi-aventis U.S. LLCMultaq | $48 | $45,36238 claims |
| Lilly USA, LLCMounjaro | $144 | $36,10934 claims |
| Boehringer IngelheimJardiance | $104 | $21,18823 claims |
| MerckVerquvo | $568 | $18,30220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in la Porte
- John McGintyRichmond$3.7M
- Steven SteinhublLafayette$2.4M
- Ravi BhagwatMunster$2.2M
- Mohan KesaniMunster$1.2M
- Vijay MehtaElkhart$925K
- William CollisFort Wayne$842K
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Wail AsfourMunster$736K
- Vijay RaoIndianapolis$706K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.